Wall Street analysts expect that Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) will report ($0.51) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Zynerba Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.50) and the lowest estimate coming in at ($0.52). Zynerba Pharmaceuticals reported earnings of ($0.44) per share in the same quarter last year, which would indicate a negative year over year growth rate of 15.9%. The firm is scheduled to issue its next earnings results on Monday, March 9th.
On average, analysts expect that Zynerba Pharmaceuticals will report full-year earnings of ($1.65) per share for the current fiscal year, with EPS estimates ranging from ($1.98) to ($1.47). For the next fiscal year, analysts expect that the business will report earnings of ($1.96) per share, with EPS estimates ranging from ($2.40) to ($1.57). Zacks’ EPS averages are an average based on a survey of analysts that follow Zynerba Pharmaceuticals.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its earnings results on Wednesday, November 6th. The company reported ($0.44) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.08.
Shares of Zynerba Pharmaceuticals stock traded up $0.08 during trading hours on Wednesday, hitting $5.71. The company’s stock had a trading volume of 267,547 shares, compared to its average volume of 1,428,174. The stock has a market cap of $130.60 million, a price-to-earnings ratio of -2.19 and a beta of 4.62. Zynerba Pharmaceuticals has a twelve month low of $2.75 and a twelve month high of $16.47. The firm has a fifty day moving average of $6.82 and a 200-day moving average of $10.11.
A number of large investors have recently added to or reduced their stakes in the business. ETF Managers Group LLC purchased a new stake in shares of Zynerba Pharmaceuticals in the 2nd quarter valued at $30,323,000. BlackRock Inc. lifted its position in shares of Zynerba Pharmaceuticals by 341.4% during the second quarter. BlackRock Inc. now owns 1,311,995 shares of the company’s stock worth $17,778,000 after purchasing an additional 1,014,749 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Zynerba Pharmaceuticals by 127.8% during the second quarter. Vanguard Group Inc. now owns 1,232,456 shares of the company’s stock worth $16,700,000 after purchasing an additional 691,342 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Zynerba Pharmaceuticals during the second quarter worth about $1,865,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Zynerba Pharmaceuticals in the second quarter valued at approximately $789,000. Institutional investors own 45.31% of the company’s stock.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder.
Featured Story: Market Capitalization
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.